Mucinous carcinoma of the breast is a well-differentiated type of adenocarcinoma accounting for 2-5% of all breast cancers. Pure mucinous carcinoma of the breast has a favorable prognosis, usually seen in post-menopausal women. Neuroendocrine differentiation has been described in both in-situ and infiltrating breast cancers. Mucinous carcinomas of the breast appear to have the greatest association with neuroendocrine differentiation. Chromogranin A and synaptophysin are specific immunohisto chemical markers of neuroendocrine differentiation. Wereporta case of mucinous carcinoma of the breast with neuroendocrine differentiation in a 67-year-old female who was treated surgically in a classical manner.

De novo metastatic prostate cancer with neuroendocrine differentiation (NED) at first presentation is extremely rare. A 65-year-old man (Gleason score 5+4, first assumed to be acinar adenocarcinoma), was referred for [99mTc]Tc-HYNIC-PSMA SPECT/CT due to low back pain. The PSA levels were 8 and <0.07 ng/mL at the time of diagnosis and prior to scintigraphy respectively. The scan revealed multiple non-PSMA-avid lesions throughout the skeleton, lung and liver, suggesting the possibility of NED or 2nd malignancy.  Second-look and review of the pathology led to change of the diagnosis to mixed small cell neuroendocrine carcinoma-acinar adenocarcinoma. This case highlights the importance of PSMA imaging in suggestion of type of the tumor which as in our case, might alter the pathologic tissue diagnosis.

Background and Objective: Neuroendocrine differentiation has not been proved to have effects in behavior of colorectal carcinomas. The aim of this study was Immunohistochemical evaluation of neuroendocrine differentiation in colorectal cancer.Patients and Methods: In this cross-sectional study, 83 paraffin blocks from patients admitted in Rasoul-e-akram Hospital, Tehran, Iran, during 2003 to 2008, were evaluated in Pathology Department. All sections were stained with immunohistochemistry method for neuron specific enolase (NSE) and Chromogranin A(CgA). Data were analyzed using SPSS 12.0.Results: Median age of patients was 56 yr. Forty four cases (53%) were female. According to TNM staging system, 11% of cases were in stage I, 29% in IIa, 7% in IIb, 2% in IIIa, 23% in IIIb, 24% IIIc and 2% were in stage IV. Thirteen cases (16%) were NSE positive, 15 cases (18.1%) were CgA positive. Two, 8 and 5 percent of the patients in grade I, II and III were CgA positive, respectively. Two, 6 and 5 percent of the patients in grade I, II and III were NSE positive. In grades II and III, NSE and CgA were significantly higher than grade I (P<0.001). CgA incidence was higher significantly in mucinous carcinomas (P<0.05).Conclusion: Less than 20% of colorectal cancers showed neuroendocrine differentiation. There was no significant relationship between NSE and CgA incidence with stage or tumor site. There was a relationship between histologic grade and above-mentioned markers; this finding may help us in our knowledge about tumor behavior.

Neuroendocrine tumors (NET) arise from neuroendocrine cells and are an exceedingly rare malignancy in the gallbladder. In this case report, a 52-year-old woman with complaints of episodic abdominal pain for two months prior was admitted to our hospital. She had no other signs and symptoms and her laboratory tests were within normal limits. Ultrasonography showed a broad-necked mass (26×12 mm) in the gallbladder for which she underwent laparoscopic cholecystectomy. The final pathological diagnosis was a high grade neuroendocrine carcinoma of the gallbladder with involvement of the lymph nodes and omentum. The patient received the chemotherapy regimens of gemcitabine plus cisplatin, followed by docetaxel plus sunitinib for her metastatic liver lesions. She also underwent radiofrequency ablation. Serial CT-scans revealed metastatic liver lesions that had decreased in size, with no significant improvement. The patient refused additional treatment and at 46 months, she was doing well with no complaints of any pain, disease recurrence, or metastatic progression.